<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Clin Oncol</journal-id><journal-title-group><journal-title>International Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">1341-9625</issn><issn pub-type="epub">1437-7772</issn><publisher><publisher-name>Springer Nature Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39799530</article-id><article-id pub-id-type="pmc">PMC11785667</article-id>
<article-id pub-id-type="publisher-id">2694</article-id><article-id pub-id-type="doi">10.1007/s10147-025-02694-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>JSCO Board of Directors Series</subject></subj-group></article-categories><title-group><article-title>Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8736-0399</contrib-id><name><surname>Imai</surname><given-names>Mitsuho</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nakamura</surname><given-names>Yoshiaki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yoshino</surname><given-names>Takayuki</given-names></name><address><email>tyoshino@east.ncc.go.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rm3gk43</institution-id><institution-id institution-id-type="GRID">grid.497282.2</institution-id><institution>Translational Research Support Section, </institution><institution>National Cancer Center Hospital East, </institution></institution-wrap>Chiba, Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rm3gk43</institution-id><institution-id institution-id-type="GRID">grid.497282.2</institution-id><institution>Department of Genetic Medicine and Services, </institution><institution>National Cancer Center Hospital East, </institution></institution-wrap>Chiba, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rm3gk43</institution-id><institution-id institution-id-type="GRID">grid.497282.2</institution-id><institution>Department of Gastroenterology and Gastrointestinal Oncology, </institution><institution>National Cancer Center Hospital East, </institution></institution-wrap>6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 Japan </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>30</volume><issue>2</issue><fpage>180</fpage><lpage>193</lpage><history><date date-type="received"><day>1</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases. In contrast, Multi-Cancer Early Detection (MCED) assays offer simultaneous screening of multiple cancers from a single liquid biopsy and identify molecular changes before symptom onset. These tests assess DNA mutations, abnormal DNA methylation patterns, fragmented DNA, and other tumor-derived biomarkers, indicating the presence of cancer and predicting its origin. Moreover, MCED assays concurrently detect multiple cancers without recommended screening protocols, potentially revolutionizing cancer screening and management. Large trials have reported promising results, achieving 50&#x02013;95% sensitivity and 89&#x02013;99% specificity for multiple cancer types. However, challenges, regarding improving accuracy, addressing ethical issues (e.g., psychosocial impact assessment), and integrating MCED into healthcare systems, must be addressed to achieve widespread adoption. Furthermore, prospective multi-institutional studies are crucial for demonstrating the clinical benefits in diverse populations. This review provides an overview of the principles, development status, and clinical significance of MCED tests, and discusses their potential and challenges.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Multi-cancer early detection</kwd><kwd>Oncology diagnostic technologies</kwd><kwd>Liquid biopsy</kwd><kwd>Cancer biomarkers</kwd><kwd>Genomic sequencing</kwd><kwd>Cancer screening</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Japan Society of Clinical Oncology 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Cancer causes approximately 10 million deaths annually worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. In Japan, it accounts for one in four deaths, making it the leading cause of mortality [<xref ref-type="bibr" rid="CR2">2</xref>]. Cancer treatment and outcomes depend on its stage. For instance, stage 1 colorectal cancer has a 5-year survival rate of 92.3%, compared to 18.4% for stage IV colorectal cancer (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>]. Therefore, prompt treatment is crucial for improving prognosis.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Five-year net survival rates for each cancer type by stage</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cancer type</th><th align="left">Stage I (%)</th><th align="left">Stage II (%)</th><th align="left">Stage III (%)</th><th align="left">Stage IV (%)</th><th align="left">Overall (%)</th></tr></thead><tbody><tr><td align="left">Breast cancer</td><td align="left">99.00</td><td align="left">94.70</td><td align="left">81.10</td><td align="left">40.50</td><td align="left">91.80</td></tr><tr><td align="left">Colorectal cancer</td><td align="left">92.30</td><td align="left">86.10</td><td align="left">76.00</td><td align="left">18.40</td><td align="left">71.40</td></tr><tr><td align="left">Lung cancer</td><td align="left">81.90</td><td align="left">52</td><td align="left">29.30</td><td align="left">8.60</td><td align="left">45.10</td></tr><tr><td align="left">Cervical cancer</td><td align="left">94.90</td><td align="left">80.10</td><td align="left">64.60</td><td align="left">26</td><td align="left">74.60</td></tr><tr><td align="left">Gastric cancer</td><td align="left">92.80</td><td align="left">66.60</td><td align="left">41</td><td align="left">6.70</td><td align="left">70.60</td></tr><tr><td align="left">Hepatocellular</td><td align="left">63.30</td><td align="left">46.10</td><td align="left">16.60</td><td align="left">4.80</td><td align="left">45.70</td></tr><tr><td align="left">Ovarian cancer</td><td align="left">90.60</td><td align="left">76.00</td><td align="left">46.90</td><td align="left">29.20</td><td align="left">65.30</td></tr><tr><td align="left">Pancreatic cancer</td><td align="left">56.20</td><td align="left">23.10</td><td align="left">6.10</td><td align="left">1.60</td><td align="left">13.10</td></tr></tbody></table></table-wrap></p><p id="Par3">Population-based screening targets gastric, colorectal, lung, breast, and cervical cancers in Japan (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. However, these screening programs do not account for 45.5% of the 1 million annual cancer cases. (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a) Moreover, participation rates in screening programs are lower than those in Western countries [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b); the participation rate for breast cancer screening is only about 40% [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Reasons for low participation include insufficient time, unawareness of the value of early cancer detection or low-cost municipal programs, and screening for discomfort-related anxiety [<xref ref-type="bibr" rid="CR18">18</xref>].<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Currently recommended cancer screening in Japan</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cancer type</th><th align="left">Screening test</th><th align="left">Target group</th><th align="left">Frequency</th><th align="left">Sensitivity</th><th align="left">Specificity</th></tr></thead><tbody><tr><td align="left" rowspan="2">Breast cancer</td><td align="left" rowspan="2">Medical interview and mammography<sup>&#x0203b;1</sup></td><td align="left">Females </td><td align="left" rowspan="2">Every 2 years</td><td align="left">50&#x02013;80%</td><td align="left">85&#x02013;90%</td></tr><tr><td align="left">aged 40 and above</td><td align="left">(mammography)</td><td align="left">(mammography)</td></tr><tr><td align="left" rowspan="2">Colorectal cancer</td><td align="left" rowspan="2">Medical interview and Fecal Occult Blood Test</td><td align="left" rowspan="2">Males and females aged 40 and above</td><td align="left" rowspan="2">Every year</td><td align="left">65&#x02013;85%</td><td align="left">95&#x02013;98%</td></tr><tr><td align="left">(Fecal occult blood test)</td><td align="left">(Fecal occult blood test)</td></tr><tr><td align="left" rowspan="2">Lung cancer</td><td align="left" rowspan="2">Medical history, chest X-ray and sputum cytology<sup>&#x0203b;2</sup></td><td align="left" rowspan="2">Males and females aged 40 and above</td><td align="left" rowspan="2">Every year</td><td align="left">30&#x02013;50%</td><td align="left">80&#x02013;90%</td></tr><tr><td align="left">(chest X-ray)</td><td align="left">(chest X-ray)</td></tr><tr><td align="left" rowspan="2">Cervical cancer</td><td align="left" rowspan="2">Medical interview, visual examination, pap smear and internal examination of the cervix</td><td align="left">Females </td><td align="left" rowspan="2">Every 2 years</td><td align="left">50&#x02013;70%</td><td align="left">85&#x02013;95%</td></tr><tr><td align="left">aged 20 and above</td><td align="left">(pap smear)</td><td align="left">(pap smear)</td></tr><tr><td align="left" rowspan="4">Gastric cancer</td><td align="left" rowspan="4">Medical interview and choice of either gastric X-ray or gastric endoscopy</td><td align="left" rowspan="4">Males and females aged 50 and above</td><td align="left" rowspan="4">Every 2 years</td><td align="left">Over 95%</td><td align="left">90&#x02013;95%</td></tr><tr><td align="left">(Gastric endoscopy)</td><td align="left">(Gastric endoscopy)</td></tr><tr><td align="left">60&#x02013;80%</td><td align="left">85&#x02013;95%</td></tr><tr><td align="left">(Gastric X-ray)</td><td align="left">(Gastric X-ray)</td></tr></tbody></table><table-wrap-foot><p>&#x0203b;1: Visual and palpatory examinations are not recommended to be performed alone</p><p>&#x0203b;2: Sputum cytology is available for those who are 50&#x000a0;years of age or older and whose smoking index (number of cigarettes per day x number of years) is 600 or higher</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Cancer type distribution and screening rates. <bold>a</bold> Distribution of cancer types in Japan. Proportion of cancer incidence by cancer type in Japan based on approximately 1 million total cancer cases per year. The dark gray segments represent the five types of cancer (colorectal, gastric, lung, breast, and cervical) currently targeted by the national screening programs, accounting for 54.5% of all incident cases. The remaining 45.5% cancer cases (shown in light gray) were not covered by existing screening programs. <bold>b</bold> Comparison of cancer screening rates across countries. Comparison of cancer screening rates among major countries. The graph shows the participation rates for breast cancer screening (dark gray), cervical cancer screening (light gray), and colorectal cancer screening (medium gray) in Japan, the United Kingdom, France, and Germany. In Japan, the screening rates for breast, cervical, and colorectal cancers are approximately 40%, which is lower than those in the other three countries</p></caption><graphic xlink:href="10147_2025_2694_Fig1_HTML" id="MO1"/></fig></p><p id="Par4">Additionally, screening methods are limited in terms of sensitivity and specificity; mammography has a sensitivity of 50&#x02013;80% and specificity of 85&#x02013;90% for breast cancer [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], resulting in false positives and negatives. Moreover, some cancers with poor prognoses, such as pancreatic and ovarian cancer [<xref ref-type="bibr" rid="CR22">22</xref>], are often excluded from current screening programs as they are difficult to detect early and are often diagnosed at advanced stages, when symptoms appear [<xref ref-type="bibr" rid="CR23">23</xref>]. Thus, new screening methods are required for such cancers.</p><p id="Par5">Multi-cancer early detection (MCED) tests can identify multiple cancers early using a single blood test by detecting cancer-derived DNA, proteins, and other biomarkers [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Numerous global clinical trials evaluating the efficacy, safety, and feasibility of MCED tests are currently underway, which will determine their potential clinical applicability [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Additionally, MCED tests could significantly impact cancer-screening paradigms and potentially overcome the limitations of current screening methods by enabling the detection of a broader spectrum of cancers through a single blood draw. However, the integration of these novel technologies into existing healthcare systems presents opportunities and challenges that warrant careful consideration.</p><p id="Par6">Therefore, this review aims to provide a comprehensive overview of MCED tests, discussing their underlying principles, current developmental status, potential clinical utility, and challenges for implementation. We aim to examine the major MCED tests under development, analyze ongoing clinical trials, and explore the implications of this technology for future cancer screening strategies.</p></sec><sec id="Sec2"><title>Principles and characteristics of MCED tests</title><sec id="Sec3"><title>Detection of cancer-derived components in the blood</title><p id="Par7">MCED tests detect cancer-derived blood components, including ctDNA mutations, methylation patterns, and cancer-associated proteins as biomarkers [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>] (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Summary of MCED tests with performance reported</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">MCE+A1:G10D test</th><th align="left">Company</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">Detection method</th><th align="left">Detectable cancer types</th></tr></thead><tbody><tr><td align="left">Aurora</td><td align="left">AnchorDx</td><td align="left">84% (Lung)</td><td align="left">99% (Lung)</td><td align="left">Targeted methylation sequencing</td><td align="left">Lung, breast, colorectal, gastric, esophageal cancers</td></tr><tr><td align="left">CancerRadar</td><td align="left">Early Diagnostics</td><td align="left">85.60%</td><td align="left">99%</td><td align="left">cfDNA fragmentation, methylation, CNVs, microbial composition</td><td align="left">Lung, colon, gastric, liver cancers</td></tr><tr><td align="left">CancerSEEK</td><td align="left">Exact Sciences</td><td align="left">62%</td><td align="left">&#x0003e;99%</td><td align="left">Multiplex PCR and single immunoassay</td><td align="left">Lung, breast, colorectal, pancreatic, gastric, hepatic, esophageal, ovarian cancers</td></tr><tr><td align="left">cfMeDIP-seq</td><td align="left">Adela Inc.</td><td align="left">AUC 0.92&#x02013;0.98</td><td align="left">&#x02013;</td><td align="left">5mC enrichment and sequencing</td><td align="left">Acute myeloid leukemia, pancreatic, lung cancers</td></tr><tr><td align="left">DEEPGENTM</td><td align="left">Quantgene</td><td align="left">43%</td><td align="left">99%</td><td align="left">Next-generation sequencing (NGS)</td><td align="left">Lung, breast, colorectal, prostate, bladder, pancreatic, liver cancers</td></tr><tr><td align="left">DELFI</td><td align="left">Delfi Diagnostics</td><td align="left">73%</td><td align="left">98%</td><td align="left">cfDNA fragmentation profiles and machine learning</td><td align="left">Lung, breast, colorectal, pancreatic, gastric, bile duct, ovarian cancers</td></tr><tr><td align="left">EDIM-TKTL1/Apo10</td><td align="left">Zyagnum AG</td><td align="left">95.80%</td><td align="left">97.30%</td><td align="left">Epitope detection in monocytes (EDIM)</td><td align="left">Oral squamous cell carcinoma, breast, prostate cancers</td></tr><tr><td align="left">EpiPanGI Dx</td><td align="left">&#x02013;</td><td align="left">85&#x02013;95% (AUC 0.88)</td><td align="left">&#x02013;</td><td align="left">Bisulfite sequencing and machine learning</td><td align="left">Gastrointestinal cancers (colorectal, pancreatic, liver, gastric, esophageal)</td></tr><tr><td align="left">Galleri<sup>&#x000ae;</sup></td><td align="left">GRAIL</td><td align="left">51.50%</td><td align="left">99.50%</td><td align="left">Targeted methylation sequencing</td><td align="left">More than 50 cancer types</td></tr><tr><td align="left">IvyGeneCORE<sup>&#x000ae;</sup> Test</td><td align="left">Laboratory for Advanced Medicine</td><td align="left">84%</td><td align="left">90%</td><td align="left">Methylation analysis</td><td align="left">Lung, breast, colorectal, liver cancers</td></tr><tr><td align="left">Omni1</td><td align="left">Avida Biomed</td><td align="left">65% (Stage I)</td><td align="left">89%</td><td align="left">Targeted methylation sequencing</td><td align="left">Lung, breast, colorectal, pancreatic, liver, ovarian cancers</td></tr><tr><td align="left">PanSeer</td><td align="left">Singlera Genomics</td><td align="left">87.60%</td><td align="left">96.10%</td><td align="left">Semi-targeted PCR libraries and sequencing</td><td align="left">Lung, colorectal, gastric, liver, esophageal cancers</td></tr><tr><td align="left">PanTum Detect<sup>&#x000ae;</sup></td><td align="left">Zyagnum AG</td><td align="left">100%</td><td align="left">96.20%</td><td align="left">EDIM-TKTL1 and EDIM-Apo10 tests</td><td align="left">Cholangiocellular, pancreatic, colorectal cancers</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Integrated analysis of multiple biomarkers</title><p id="Par8">The FDA-approved Guardant Health Shield test combines genomic mutations, methylation, and DNA fragmentation patterns for early colorectal cancer detection. The ECLIPSE study (n&#x02009;&#x0003e;&#x02009;20,000) demonstrated its efficacy in average-risk adults [<xref ref-type="bibr" rid="CR26">26</xref>] and identified 83% colorectal cancer cases, with a sensitivity of 65%, 100%, 100%, and 100% for stages I&#x02013;IV, respectively, and detected 13% of advanced adenomas. Additionally, it achieved 88% and 65% sensitivity for pathologically confirmed Stage I&#x02013;III CRC and Stage I, respectively. Thus, these results demonstrate improved early CRC detection by combining multiple biomarkers [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. Moreover, the ECLIPSE study included a diverse cohort representative of the Unites States (US) population, thus enhancing the generalizability of the results. Although Shield is currently focused on colorectal cancer detection, the successful integration of multiple biomarkers in this test lays a promising foundation for the future development of MCED tests.</p><p id="Par9">In contrast to Shield, CancerSEEK can analyze eight cancer-associated proteins and 16 cancer gene mutations simultaneously. Combining gene mutations with protein biomarkers increases the sensitivity of the test from 43 to 69%. [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>] Similarly, MCED tests combining ctDNA mutations or methylation patterns with protein biomarkers have shown improved sensitivity, reaching 85% and 87.3%, respectively, with a specificity&#x02009;&#x0003e;&#x02009;99% [<xref ref-type="bibr" rid="CR41">41</xref>]. The Galleri test analyzes genetic regions with cancer-specific methylation patterns [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par10">Bioinformatics is crucial for selecting the optimal combination of biomarkers for developing MCED tests, as it enhances accuracy based on various biological principles. These integrated approaches underscore the potential of multi-biomarker analysis in improving MCED test performance across various cancer types and stages.</p></sec><sec id="Sec5"><title>Machine learning-based interpretation of cancer signals</title><p id="Par11">Machine learning algorithms are crucial for interpreting MCED biomarker data [<xref ref-type="bibr" rid="CR42">42</xref>]. The Galleri test uses a logistic regression model with methylation profile data [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. If the cancer signal exceeds a threshold, it suggests the presence of cancer and predicts tissue origin. For instance, Klein et al. (2021) showed 51.5% sensitivity and 99.5% specificity for Stages I&#x02013;III cancers, with 90.1% CSO prediction accuracy [<xref ref-type="bibr" rid="CR27">27</xref>]. Whereas CancerSEEK uses a random forest model to identify the best cutoff from eight proteins and 16 gene mutations [<xref ref-type="bibr" rid="CR44">44</xref>]. Thus, machine learning offers data-driven decision-making, however, challenges for its application include interpretability, generalizability, and reproducibility across populations and environments, necessitating careful validation for algorithm selection and hyperparameter tuning.</p></sec></sec><sec id="Sec6"><title>Potential utility of MCED tests</title><sec id="Sec7"><title>Early detection of multiple cancers with a single test</title><p id="Par12">Compared to traditional screening methods, which require organ specific tests, MCED tests can detect more than 50 types of cancer in a single test, markedly improving screening efficiency when combined with conventional screening tests [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Additionally, MCED tests can detect pancreatic and ovarian cancers, which are not covered by regular screening. Early detection of these cancers through MCED tests can improve treatment outcomes, as symptoms often appear only in advanced stages. Thus, detecting these cancers at an asymptomatic stage using MCED testing can improve treatment outcomes [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec8"><title>Streamlining cancer screening and health economic effects</title><p id="Par13">The treatment of advanced-stage cancer requires extensive medical resources. MCED tests aid in early cancer detection resulting in early stage treatment, which reduces cancer treatment costs and MCED tests streamline cancer screening. However, their cost-effectiveness depends on factors such as test performance, cost, and compliance rate [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. A study estimated that early detection using MCED tests could reduce cancer treatment costs by $260 billion annually [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec9"><title>Improved quality of life and patient empowerment</title><p id="Par14">Advanced cancer treatment is highly stressful and lowers the quality of life (QOL), whereas early stage cancer treatment is minimally invasive. Thus, MCED tests can reduce patient anxiety, increase treatment autonomy, raise cancer awareness, and promote preventive behaviors. Moreover, patients become aware of their cancer risk by undergoing regular MCED testing. Thus, they are more likely to engage in preventive behaviors such as lifestyle improvements and participation in cancer screening programs [<xref ref-type="bibr" rid="CR36">36</xref>] [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec></sec><sec id="Sec10"><title>Challenges of MCED tests</title><sec id="Sec11"><title>Improving sensitivity and specificity</title><p id="Par15">Although effective, current MCED tests require improvement, especially for stage I cancer detection. Novel biomarkers and technologies, such as cfDNA methylation patterns and miRNAs, along with ultrasensitive sequencing and digital polymerase chain reaction (PCR), can potentially increase sensitivity [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. Regarding specificity, elucidating the causes of false positive results in healthy individuals is important. Physiological changes caused by aging, lifestyle habits, and inflammation can affect cancer-related biomarkers; therefore, clarifying their effects is important [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec12"><title>Counseling and follow-up</title><p id="Par16">Despite promising results, MCED tests can result in false positives or negatives, requiring specialized professionals for result interpretation and follow-up. Patients with positive MCED but negative diagnostic tests must be monitored owing to increased cancer risk [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Therefore, collaboration with patient advocates is crucial for education and equitable access to counseling.</p><p id="Par17">Furthermore, the cost of follow-up testing after positive MCED results poses a significant challenge. When MCED tests are positive but conventional diagnostic tests are negative, insurance coverage for continued surveillance becomes a critical issue. Currently, most healthcare systems lack established policies regarding insurance coverage for follow-up examinations. This issue may impose financial burdens on patients and impact the practical implementation of MCED testing programs. Therefore, healthcare systems and insurance providers must develop comprehensive policies that address the costs of both the initial MCED testing and subsequent follow-up examinations to ensure equitable access to this technology. These initiatives can minimize financial barriers and maximize the public health benefits offered by MCED technology [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec13"><title>Challenges in clinical trials</title><p id="Par18">MCED clinical trials face challenges in determining optimal testing intervals and endpoints, considering cancer type, progression rate, frequency, endpoints, detection, false-positives, and overdiagnosis rates [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Additionally, clinical trials for MCED tests are costly, time-consuming, and require large sample sizes, long-term follow-up, and specialized molecular diagnostic platforms for cancer type sensitivity and specificity evaluation [<xref ref-type="bibr" rid="CR46">46</xref>].</p></sec><sec id="Sec14"><title>Development status and clinical trials of major MCED tests*</title><sec id="Sec15"><title>1. Galleri</title><p id="Par19">GRAIL Galleri (GRAIL, Inc., Menlo Park, California, USA) is the first commercially available blood-based MCED test that combines genome-wide methylation changes in cfDNA and machine learning to detect cancer and predict its tissue of origin. Circulating Cell-free Genome Atlas (CCGA) studies laid the foundation for developing and refining the GRAIL MCED test, involving approximately 15,000 patients with and without cancer across 142 sites in the US and Canada. The original GRAIL Galleri test was refined for CCGA1 and 2 cohorts and validated using CCGA3 cohort. The CCGA1 cohort comprised 2,800 participants, divided into newly diagnosed patients with and without cancer, who were further divided into the training and independent test sets. With a specificity of 98% in the CCGA1 training set, the sensitivity for stage I&#x02013;III cancers (N&#x02009;=&#x02009;117) was 54%. Whole-genome bisulfite sequencing showed the best performance in predicting stages I&#x02013;III cancers. The final CCGA study, comprising the CCGA3 cohort, aimed to validate a refined MCED test version for use as a screening tool. This prespecified sub study included 4,077 participants in an independent validation set. The specificity and overall sensitivity for the detection of cancer signals were 99.5% and 51.5%, respectively. The sensitivity for stage I&#x02013;III cancer was 40.7% for all cancers. Cancer signals were detected in&#x02009;&#x0003e;&#x02009;50 cancers. The overall accuracy of CSO prediction for true positives was 88.7% [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par20">The PATHFINDER study was the first to evaluate the refined versions of the GRAIL MCED test in 6,662 individuals aged&#x02009;&#x02265;&#x02009;50&#x000a0;years with cancer risk factors. It showed a specificity, positive predictive value (PPV), and negative predictive value (NPV) of 99.1%, 43.1%, and 98.5%, respectively. The study found that 71% of the Galleri-positive cancers were types without standard screening tests, and half of these were detected at stage I/II. These results demonstrates the benefit of the Galleri test for early detection, particularly for challenging-to-detect cancers [<xref ref-type="bibr" rid="CR26">26</xref>]. In contrast, the NHS-Galleri trial, a randomized controlled study, involved 140,000 individuals aged 50&#x02013;77 with no cancer diagnosis in the last three years, randomly assigned to intervention or control arms. The primary objective was to determine whether there was a statistically significant reduction in stage III and IV cancer incidence in the intervention arm compared to that in the control arm 3&#x02013;4&#x000a0;years after randomization. The NHS-Galleri trial considered stage shift as a mortality endpoint [<xref ref-type="bibr" rid="CR28">28</xref>], however, mortality trials are warranted to determine the true benefit of MCED tests. Although the Galleri test has shown high accuracy since May 2024, the NHS awaits the final results, expected in 2026, before considering a large-scale rollout [<xref ref-type="bibr" rid="CR47">47</xref>]. The trial ended in July 2024.</p><p id="Par21">GRAIL conducted the PATHFINDER 2 (NCT05155605) study with over 35,000 participants aged&#x02009;&#x02265;&#x02009;50&#x000a0;years for cancer screening evaluation. This study aims to assess the safety and performance of the Galleri test, with results for the first 25,000 participants expected by the end of 2025. Thus, the NHS-Galleri trial and other studies will provide additional clinical evidence for the Galleri test, supporting its application for FDA premarket approval under Breakthrough Device Designation.</p></sec><sec id="Sec16"><title>2. CancerSEEK</title><p id="Par22">CancerSEEK (currently developed as Cancerguard&#x02122; by Exact Sciences Corporation, Madison, Wisconsin, USA) is an MCED test developed by Vogelstein et al. at Johns Hopkins University [<xref ref-type="bibr" rid="CR48">48</xref>] The test detects eight types of cancer (ovarian, liver, gastric, pancreatic, esophageal, colorectal, lung, and breast cancer) using eight protein markers (CA-125, CEA, CA19-9, Prolactin, HGF, Osteopontin, Myeloperoxidase, TIMP-1) and 16 cancer gene mutations <italic>(TP53, KRAS,</italic> etc.) in the blood. Commercially available immunoassay kits were used to analyze the protein markers and a proprietary PCR-based assay was used to analyze gene mutations. PCR was used to amplify hotspot mutations in 16 cancer genes after cfDNA extraction to detect mutations. Gene and protein data were analyzed using a machine-learning model to determine the probability of cancer.</p><p id="Par23">The first clinical trial for CancerSEEK involved 1,005 patients with cancer and 812 controls [<xref ref-type="bibr" rid="CR23">23</xref>] and detected eight types of cancer with 69.8% sensitivity and 99. When only stage II or higher was used, the sensitivity was 83.0%. CancerSEEK accurately found the primary site in 39% of positive cases based on the tissue of origin.</p><p id="Par24">CancerSEEK is sensitive to detecting hard-to-detect cancers such as ovarian cancer (98%), hepatocellular carcinoma (95%), and gastric cancer (90%). However, it has only approximately 40% sensitivity for stage I cancers, warranting improvements [<xref ref-type="bibr" rid="CR23">23</xref>]. The DETECT-A study evaluated the utility of CancerSEEK [<xref ref-type="bibr" rid="CR23">23</xref>]. This prospective interventional study included 10,006 women aged 65&#x02013;75&#x000a0;years with no history of cancer. It assessed a screening method using the CancerSEEK blood test and PET/CT, and 61 cancer gene mutations and protein markers using blood tests. The results showed that the blood test alone had sensitivity, specificity, PPV, and NPV of 27.1%, 98.9%, 19.4%, and 99.3%, respectively. Whereas combining PET/CT improved the specificity and PPV to 99.6% and 28.3%, respectively. Among the detected cancers, 65% were in the early stages (stage I/II). Blood tests revealed 31% of the 45 cancers in seven organs with no standard screening methods. Currently, CancerSEEK has received breakthrough device designation from the FDA.</p><p id="Par25">Updated data from the DETECT-A and ASCEND-2 studies were presented at the 2024 American Association for Cancer Research Annual Meeting, showing the recent progress in CancerSEEK development (Cancerguard) [<xref ref-type="bibr" rid="CR49">49</xref>]. The ASCEND-2 study confirmed the effectiveness of the prototype Cancerguard test in 11,000 participants, detecting cancers without established screening methods, with a 50.9% sensitivity and 98.5% specificity. Additionally, the DETECT-A study found that the early version of CancerSEEK detected cancer in patients with precancerous conditions [<xref ref-type="bibr" rid="CR46">46</xref>]. Moreover, the Cancerguard test, which is currently under development, aims to detect multiple early-stage cancers from a single blood sample by leveraging the sensitivity of multiple biomarker classes while maintaining high specificity.</p></sec><sec id="Sec17"><title>3. Other MCED tests</title><p id="Par26">Several other MCED tests are currently underway (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) which have different principles and target cancer types, sensitivities, and specificities. PanSeer by Singlera Genomics in China is an MCED test that uses cfDNA methylation patterns. A Chinese study of 123,115 participants used PanSeer to detect cancer from asymptomatic blood samples and identified 95% patients who were later diagnosed with cancer.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Prospective clinical trials evaluating performance of MCED tests</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Sponsor</th><th align="left">Trial name</th><th align="left">Trial ID</th><th align="left">Study type</th><th align="left">Cancer type</th><th align="left">Enrollment</th><th align="left">Age</th><th align="left">Period</th><th align="left">Status</th><th align="left">Country</th><th align="left">Endpoint</th></tr></thead><tbody><tr><td align="left">GRAIL</td><td align="left">CCGA</td><td align="left">NCT02889978</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">15,254</td><td align="left">&#x02265;20 years</td><td align="left">Aug 2016 &#x02013; Mar 2024</td><td align="left">Active (not recruiting)</td><td align="left">USA</td><td align="left">Positive predictive value</td></tr><tr><td align="left">GRAIL</td><td align="left">STRIVE</td><td align="left">NCT03085888</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">99,481</td><td align="left">&#x02265;18 years (female)</td><td align="left">Feb 2017 &#x02013; May 2025</td><td align="left">Active</td><td align="left">USA</td><td align="left">&#x02013;</td></tr><tr><td align="left">GRAIL</td><td align="left">PATHFINDER</td><td align="left">NCT04241796</td><td align="left">Interventional</td><td align="left">Cancer</td><td align="left">6662</td><td align="left">&#x02265;50 years</td><td align="left">Dec 2019 &#x02013; Jan 2022</td><td align="left">Completed</td><td align="left">USA</td><td align="left">Number of tests required for diagnosis after positive result</td></tr><tr><td align="left">GRAIL</td><td align="left">SUMMIT</td><td align="left">NCT03934866</td><td align="left">Observational</td><td align="left">Lung cancer</td><td align="left">13,035</td><td align="left">55&#x02013;77 years</td><td align="left">May 2024 &#x02013; Aug 2030</td><td align="left">Completed</td><td align="left">UK</td><td align="left">Performance of cfNA signals</td></tr><tr><td align="left">GRAIL</td><td align="left">SYMPLIFY</td><td align="left">ISCRTN10226380</td><td align="left">RCT</td><td align="left">&#x02013;</td><td align="left">6238</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Active</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">GRAIL</td><td align="left">NHS-Galleri</td><td align="left">NCT05611632</td><td align="left">Interventional</td><td align="left">Cancer</td><td align="left">1,40,000</td><td align="left">50&#x02013;77 years</td><td align="left">Aug 2021 &#x02013; Feb 2026</td><td align="left">Active (not recruiting)</td><td align="left">UK</td><td align="left">Absolute numbers of stage III-IV cancers</td></tr><tr><td align="left">GRAIL</td><td align="left">PATHFINDER 2</td><td align="left">NCT05155605</td><td align="left">Interventional</td><td align="left">Cancer</td><td align="left">20,000</td><td align="left">&#x02265;50 years</td><td align="left">Dec 2021 &#x02013; Dec 2027</td><td align="left">Recruiting</td><td align="left">USA</td><td align="left">Safety of invasive tests due to false positives</td></tr><tr><td align="left">GRAIL</td><td align="left">REFLECTION</td><td align="left">NCT05205967</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">17,000</td><td align="left">&#x02265;22 years</td><td align="left">Aug 2021 &#x02013; Aug 2026</td><td align="left">Recruiting</td><td align="left">USA</td><td align="left">Detection performance for invasive cancers</td></tr><tr><td align="left">Exact Sciences</td><td align="left">ASCEND</td><td align="left">NCT04213326</td><td align="left">Observational</td><td align="left">&#x02013;</td><td align="left">6400</td><td align="left">&#x02265;50 years</td><td align="left">Nov 2019 &#x02013; Jan 2021</td><td align="left">Completed</td><td align="left">&#x02013;</td><td align="left">Development of CancerSEEK assay</td></tr><tr><td align="left">Exact Sciences</td><td align="left">DETECT-A</td><td align="left">&#x02013;</td><td align="left">Interventional</td><td align="left">&#x02013;</td><td align="left">9911</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Recruiting</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Burning Rock</td><td align="left">THUNDER</td><td align="left">NCT04820868</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">2508</td><td align="left">40&#x02013;75 years</td><td align="left">Apr 2021 &#x02013; Apr 2022</td><td align="left">Completed</td><td align="left">China</td><td align="left">Detection of 6 cancers and TOO accuracy</td></tr><tr><td align="left">Burning Rock</td><td align="left">PREDICT</td><td align="left">NCT04817306</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">14,026</td><td align="left">40&#x02013;75 years</td><td align="left">Mar 2021 &#x02013; Mar 2023</td><td align="left">Recruiting</td><td align="left">China</td><td align="left">Sensitivity and TOO accuracy at 90/95/98% specificity</td></tr><tr><td align="left">Burning Rock</td><td align="left">PRESCIENT</td><td align="left">NCT04822792</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">11,879</td><td align="left">40&#x02013;75 years</td><td align="left">Mar 2021 &#x02013; Jun 2023</td><td align="left">Unknown</td><td align="left">China</td><td align="left">Detection of 22 cancers and TOO accuracy</td></tr><tr><td align="left">Burning Rock</td><td align="left">PROMISE</td><td align="left">NCT04972201</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">2305</td><td align="left">40&#x02013;75 years</td><td align="left">Jul 2021 &#x02013; Mar 2022</td><td align="left">Unknown</td><td align="left">China</td><td align="left">Sensitivity of cfDNA mutation, methylation, miRNA</td></tr><tr><td align="left">Burning Rock</td><td align="left">PREVENT</td><td align="left">NCT05227534</td><td align="left">Interventional</td><td align="left">Cancer</td><td align="left">12,500</td><td align="left">40&#x02013;75 years</td><td align="left">Jun 2022 &#x02013; Dec 2028</td><td align="left">Recruiting</td><td align="left">China</td><td align="left">QOL changes in test-positive individuals</td></tr><tr><td align="left">Singlera Genomics</td><td align="left">FuSion</td><td align="left">NCT05159544</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">60,000</td><td align="left">40&#x02013;75 years</td><td align="left">Jul 2021 &#x02013; Dec 2024</td><td align="left">Recruiting</td><td align="left">China</td><td align="left">Development of multi-omics model</td></tr><tr><td align="left">Gene Solutions</td><td align="left">K-DETEK</td><td align="left">NCT05227261</td><td align="left">Observational</td><td align="left">5 cancers</td><td align="left">10,000</td><td align="left">&#x02265;40 years</td><td align="left">Apr 2022 - Dec 2023</td><td align="left">Completed</td><td align="left">Vietnam</td><td align="left">Performance in early cancer detection</td></tr><tr><td align="left">Gene Solutions</td><td align="left">K-ACCELERATE</td><td align="left">NCT06391749</td><td align="left">Observational</td><td align="left">5 cancers</td><td align="left">16,666</td><td align="left">Adults</td><td align="left">Apr 2024 - Oct 2024</td><td align="left">Recruiting</td><td align="left">Vietnam</td><td align="left">Cancer detection in symptomatic individuals</td></tr><tr><td align="left">Elypta</td><td align="left">LEV87A</td><td align="left">NCT05235009</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">9170</td><td align="left">18&#x02013;80 years</td><td align="left">Feb 2022 &#x02013; Mar 2025</td><td align="left">Recruiting</td><td align="left">Sweden</td><td align="left">Sensitivity and specificity of GAGome MCED test</td></tr><tr><td align="left">Elypta</td><td align="left">LEV93A</td><td align="left">NCT05295017</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">1256</td><td align="left">55&#x02013;80 years</td><td align="left">Mar 2022 &#x02013; Mar 2025</td><td align="left">Recruiting</td><td align="left">UK</td><td align="left">Sensitivity and specificity of plasma GAGome MCED test</td></tr><tr><td align="left">Elypta</td><td align="left">MCED of Firefighters</td><td align="left">NCT05780957</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">1000</td><td align="left">Adults</td><td align="left">Mar 2023 - Dec 2030</td><td align="left">Recruiting</td><td align="left">USA</td><td align="left">Sensitivity and specificity of plasma and urine GAGome</td></tr><tr><td align="left">Geneplus-Beijing Co.</td><td align="left">PREDICT</td><td align="left">NCT04383353</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">14,026</td><td align="left">40&#x02013;75 years</td><td align="left">Jul 2020 &#x02013; Mar 2023</td><td align="left">Unknown</td><td align="left">China</td><td align="left">Sensitivity and specificity of cfDNA methylation model</td></tr><tr><td align="left">Yonsei University</td><td align="left">&#x02013;</td><td align="left">NCT06231953</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">4000</td><td align="left">Adults</td><td align="left">Oct 2022 &#x02013; Dec 2024</td><td align="left">Recruiting</td><td align="left">South Korea</td><td align="left">Whole genome sequencing of circulating DNA</td></tr><tr><td align="left">Shanghai Weihe Medical Laboratory</td><td align="left">PROFOUND</td><td align="left">NCT06217900</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">4000</td><td align="left">Adults</td><td align="left">Dec 2023 &#x02013; Mar 2027</td><td align="left">Recruiting</td><td align="left">China</td><td align="left">Performance of cfDNA methylation model</td></tr><tr><td align="left">Nanjing Shihejiyin Technology</td><td align="left">The Jinling Cohort</td><td align="left">NCT06011694</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">2000</td><td align="left">Adults</td><td align="left">Jun 2022 &#x02013; May 2027</td><td align="left">Recruiting</td><td align="left">China</td><td align="left">Performance of MERCURY</td></tr><tr><td align="left">MiRXES</td><td align="left">CADENCE</td><td align="left">NCT05633342</td><td align="left">Observational</td><td align="left">9 cancers</td><td align="left">15,000</td><td align="left">Adults</td><td align="left">Jul 2022 &#x02013; May 2024</td><td align="left">Recruiting</td><td align="left">Singapore</td><td align="left">Discovery of multi-omics cancer biomarkers</td></tr><tr><td align="left">Lanxi Hospital</td><td align="left"> Combination of Chinese Traditional and Western Medicine in Lanxi City</td><td align="left">NCT06200051</td><td align="left">Observational</td><td align="left">&#x02013;</td><td align="left">15,000</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Completed Dec 2024</td><td align="left">China</td><td align="left">Program coverage, navigator guidance rate, etc.</td></tr><tr><td align="left">Harbinger Health</td><td align="left">CORE-HH</td><td align="left">NCT05435066</td><td align="left">Observational</td><td align="left">&#x02013;</td><td align="left">2,70,000</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">Completed Jul 2026</td><td align="left">&#x02013;</td><td align="left">Cancer detection by Harbinger Test</td></tr><tr><td align="left">Delfi Diagnostics</td><td align="left">DELFI-L101</td><td align="left">NCT04825834</td><td align="left">Observational</td><td align="left">Lung cancer, etc.</td><td align="left">2660</td><td align="left">&#x02265;50 years</td><td align="left">Mar 2021 &#x02013; May 2026</td><td align="left">Recruiting</td><td align="left">USA</td><td align="left">Sensitivity and specificity for lung cancer detection</td></tr><tr><td align="left">Adela</td><td align="left">CAMPERR</td><td align="left">NCT05366881</td><td align="left">Observational</td><td align="left">Brain tumor</td><td align="left">7000</td><td align="left">&#x02265;40 years</td><td align="left">May 2022 &#x02013; Dec 2026</td><td align="left">Recruiting</td><td align="left">USA</td><td align="left">Cancer detection, tissue type identification, etc.</td></tr><tr><td align="left">Freenome Holdings</td><td align="left">Vallania</td><td align="left">NCT05254834</td><td align="left">Observational</td><td align="left">Cancer</td><td align="left">5400</td><td align="left">&#x02265;30 years</td><td align="left">Feb 2022 &#x02013; Jun 2025</td><td align="left">Recruiting</td><td align="left">USA</td><td align="left">Comparison of blood samples in case-control</td></tr><tr><td align="left">Centre Georges Francois Leclerc</td><td align="left">EXODIAG</td><td align="left">NCT02662621</td><td align="left">Interventional</td><td align="left">Cancer</td><td align="left">71</td><td align="left">&#x02265;18 years</td><td align="left">Dec 2015 &#x02013; Apr 2019</td><td align="left">Completed</td><td align="left">France</td><td align="left">HSP70 exosome concentration in blood and urine</td></tr></tbody></table></table-wrap></p><p id="Par27">slearning algorithms, respectively, to identify circulating tumor-associated cells. OneTest has a specificity and sensitivity of approximately 80% and 82% for men and 62% for women, respectively, whereas TruCheck has a sensitivity, specificity, and accuracy of 1%, 99.9%, and 93.1%, respectively [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par28">In addition to these blood-based approaches, emerging urine-based MCED systems merit consideration as potential complementary screening methods. These tests offer advantages, such as non-invasive sample collection and the possibility of home-based testing, which could enhance screening accessibility and patient compliance. However, urine-based approaches face unique technical challenges, including lower concentrations of tumor-derived materials compared with blood, variable sample quality, and distinct biomarker degradation patterns that may affect analytical stability. Current urine-based MCED platforms remain in early development stages, with performance characteristics yet to be established relative to blood-based tests. Future comparative studies will be crucial to determine how these approaches might complement existing cancer screening strategies [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par29">The US National Cancer Institute announced a clinical trial network called the Cancer Screening Research Network (CSRN) to assess new cancer screening technologies. The CSRN pilot study, &#x0201c;Vanguard Study on Multi-Cancer Detection,&#x0201d; in 2024, which enrolled 24,000 participants to test the feasibility of MCEDs. This RCT compares cancer detection tests to control groups. The results will inform the Vanguard study, a randomized controlled trial, which aims to validate the MCED tests. A long-term trial of 225,000&#x02013;300,000 volunteers aged 45&#x02013;70 to determine if MCED affects cancer and all-cause mortality [<xref ref-type="bibr" rid="CR55">55</xref>].</p></sec></sec><sec id="Sec18"><title>Integration into cancer screening systems and cost efficiency</title><p id="Par30">In future, MCED tests must be integrated into the current cancer screening systems for clinical practice. If the MCED test is positive, further diagnostic tests should be performed for a definitive diagnosis. Therefore, a diagnostic test system is required. Additionally, sufficient expertise is required for MCED test result interpretation and explanation; therefore, development of educational programs for healthcare professionals, health insurers, and patients is crucial. MCED tests may also affect cancer-screening programs, potentially reducing participation in conventional programs, while identifying high-risk individuals for targeted screening. Therefore, the relationship between MCED tests and cancer screening programs must be clarified, the cost-effectiveness of MCED tests and existing screening programs must be evaluated, and the impact of MCED testing on participation rates in existing screening programs must be monitored to establish appropriate diagnostic and follow-up systems for MCED test-positive individuals [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>].</p></sec><sec id="Sec19"><title>Potential trials to evaluate MCED testing performance</title><p id="Par31">Three main types of study designs can be used to evaluate the performance of MCED tests [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR45">45</xref>] [<xref ref-type="bibr" rid="CR59">59</xref>] [<xref ref-type="bibr" rid="CR60">60</xref>].<list list-type="order"><list-item><p id="Par32">Case&#x02013;control study: Samples are collected from cohorts with and without cancer to evaluate the sensitivity, specificity, and performance metrics of the MCED test (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a).</p></list-item><list-item><p id="Par33">Single-arm trial: The MCED test is administered to individuals eligible for cancer screening without symptoms or prior diagnosis, and positive cases undergo further diagnostic procedures (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b).</p></list-item><list-item><p id="Par34">Randomized controlled trial: Participants are randomly assigned to either MCED test or control group to evaluate the clinical benefits of MCED tests, including cancer stage shift and reduced mortality (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c).</p></list-item></list><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Evaluation of MCED test performance. <bold>a</bold> In this model, samples were collected from a cohort of patients with and without cancer. The MCED test was performed on these samples to assess its sensitivity, specificity, and other performance characteristics by comparing the test results between the two cohorts. <bold>b</bold> In this model, the MCED test was administered to participants, and those who tested positive underwent diagnostic testing to confirm their cancer status. The positive predictive value and cancer detection rate of the MCED test was assessed based on the results of the diagnostic testing during the trial period. <bold>c</bold> In this model, participants were randomly assigned to either the MCED test group or a control group that does not receive the MCED test. Both groups were followed up for a defined period to determine their cancer status. The clinical utility of the MCED test, such as its ability to shift the cancer stage at diagnosis and reduce cancer-related mortality, were evaluated by comparing outcomes between the two groups</p></caption><graphic xlink:href="10147_2025_2694_Fig2_HTML" id="MO2"/></fig></p><p id="Par35">By applying these study designs, researchers can comprehensively evaluate the efficacy and safety of MCED tests and establish them as new cancer-screening options.</p><p id="Par36">MCED tests have shown great potential in identifying early stage cancers, particularly in high-risk populations such as those with hereditary cancer syndromes. For example, a recent study, "cfDNA Early Cancer Detection in LFS," investigated the effectiveness of MCED in detecting early-stage cancers in patients with the Li-Fraumeni Syndrome (LFS). This study showed promising results, with an overall sensitivity of 81.6% and the ability to predict cancer localization [<xref ref-type="bibr" rid="CR61">61</xref>].</p><p id="Par37">Based on these findings, we suggest the need for clinical trials to evaluate MCED tests for hereditary cancer syndromes. These trials should also evaluate the accuracy and psychological impact of MCED tests in detecting early stage cancer compared with standard surveillance methods in multiple centers.</p><p id="Par38">Additionally, such trials could assess the potential of the MCED tests in terms of:<list list-type="order"><list-item><p id="Par39">Comprehensive screening of multiple cancer types associated with specific syndromes.</p></list-item><list-item><p id="Par40">Reducing the burden of frequent invasive screening procedures in high-risk groups.</p></list-item><list-item><p id="Par41">Improving patient quality of life through less invasive and more efficient screening methods.</p></list-item></list></p><p id="Par42">Successful MCED tests may enhance personalized cancer surveillance and improve the early detection rates and outcomes in high-risk individuals. Additionally, clinical trial results may help develop guidelines for using MCED tests in hereditary cancer syndromes and support the use of MCED in cancer screening. Furthermore, these studies should evaluate the cost-effectiveness and patient-reported outcomes of integrating MCED tests into existing screening protocols for high-risk populations, informing evidence-based policies for optimizing patient-centered cancer detection strategies.</p><p id="Par43">Based on these three trial types, we propose a stepwise approval system for MCED technologies that parallels the phased approach used in drug development:</p><p id="Par44">Stage 1 (Safety and Technical Validation): Case&#x02013;control studies to establish analytical validity, safety, and preliminary performance metrics.</p><p id="Par45">Stage 2 (Clinical Validation): Single-arm trials in intended-use populations to validate clinical performance and establish positive/negative predictive values in real-world settings.</p><p id="Par46">Stage 3 (Clinical Utility): Randomized controlled trials to demonstrate impact on patient outcomes, including stage shift and mortality reduction.</p><p id="Par47">This framework could provide a standardized pathway for regulatory approval, while ensuring the appropriate evaluation of MCED technologies at each developmental stage. Such a system would help companies plan their development programs more effectively and provide regulators with clear criteria for assessment.</p></sec></sec><sec id="Sec20"><title>Conclusions</title><p id="Par48">The review discusses the development status and clinical significance of MCED tests, highlighting their high efficacy and accuracy. It also addresses challenges such as sensitivity, specificity, integration, and potential risks like overdiagnosis and overtreatment. Moreover, our review highlights the need for research and awareness of MCED test values, which are crucial for maximizing their potential in cancer screening, necessitating collaboration between industry, academia, and government.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding</title><p>This research received no specific grants from any funding agency in the public, commercial, or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par49">M.I. reports advisory role from Sumitomo Co., Ltd., Exact Sciences Corporation.; speakers&#x02019; bureau from Chugai Pharmaceutical Co., Ltd.; research funding from Merck Sharp and Dohme, Inc. Y.N. reports advisory role from Guardant Health Pte Ltd., Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Exact Sciences Corporation, and Gilead Sciences, Inc.; speakers&#x02019; bureau from Guardant Health Pte Ltd., MSD K.K., Eisai Co., Ltd., Zeria Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., CareNet, Inc., Hisamitsu Pharmaceutical Co., Inc., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Becton, Dickinson and Company, Guardant Health Japan Corp; research funding from Seagen Inc., Genomedia Inc., Guardant Health AMEA, Inc., Guardant Health, Inc., Tempus Labs, Inc., Roche Diagnostics K.K., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd. T.Y. reports honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., and MSD K.K; consulting fee from Sumitomo Corp.; and research grant from Amgen K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., FALCO biosystems Ltd., Genomedia Inc., Medical &#x00026; Biological Laboratories Co., Ltd., Merus N.V., Molecular Health GmbH, MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Roche Diagnostics K.K., Sanofi K.K., Sysmex Corp., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par50">This study did not involve human subjects or animal experiments, and therefore did not require ethical approval.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229&#x02013;263. 10.3322/caac.21834<pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Ministry of Health, Labour and Welfare, Japan (2023) Vital statistics of Japan 2022 (final data). <ext-link ext-link-type="uri" xlink:href="https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei22/index.html">https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei22/index.html</ext-link>. Accessed 9 Jan 2025</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Cancer Information Service, National Cancer Center, Japan. Annual Survival Report of Hospital-Based Cancer Registries. . <ext-link ext-link-type="uri" xlink:href="https://hbcr-survival.ganjoho.jp/">https://hbcr-survival.ganjoho.jp/</ext-link> Accessed 25 June 2024</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Kolb</surname><given-names>TM</given-names></name><name><surname>Lichy</surname><given-names>J</given-names></name><name><surname>Newhouse</surname><given-names>JH</given-names></name></person-group><article-title>Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations</article-title><source>Radiology</source><year>2002</year><volume>225</volume><issue>1</issue><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1148/radiol.2251011667</pub-id><pub-id pub-id-type="pmid">12355001</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kolb TM, Lichy J, Newhouse JH (2002) Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 225(1):165&#x02013;175. 10.1148/radiol.2251011667<pub-id pub-id-type="pmid">12355001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Rex</surname><given-names>DK</given-names></name><name><surname>Schoenfeld</surname><given-names>PS</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>Quality indicators for colonoscopy</article-title><source>Gastrointest Endosc</source><year>2015</year><volume>81</volume><issue>1</issue><fpage>31</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2014.07.058</pub-id><pub-id pub-id-type="pmid">25480100</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Rex DK, Schoenfeld PS, Cohen J (2015) Quality indicators for colonoscopy. Gastrointest Endosc 81(1):31&#x02013;53. 10.1016/j.gie.2014.07.058<pub-id pub-id-type="pmid">25480100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>TR</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Conell</surname><given-names>C</given-names></name><etal/></person-group><article-title>Complications of colonoscopy in an integrated health care delivery system</article-title><source>Ann Intern Med</source><year>2006</year><volume>145</volume><issue>12</issue><fpage>880</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-145-12-200612190-00004</pub-id><pub-id pub-id-type="pmid">17179057</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Levin TR, Zhao W, Conell C et al (2006) Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 145(12):880&#x02013;886. 10.7326/0003-4819-145-12-200612190-00004<pub-id pub-id-type="pmid">17179057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Iinuma</surname><given-names>T</given-names></name><name><surname>Tateno</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name></person-group><article-title>Comparison of two types of mass screening for lung cancer in terms of cost-effectiveness: indirect chest X-ray vs LSCT</article-title><source>Nippon Igaku Hoshasen Gakkai Zasshi</source><year>1994</year><volume>54</volume><issue>10</issue><fpage>943</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">7971185</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Iinuma T, Tateno Y, Matsumoto T (1994) Comparison of two types of mass screening for lung cancer in terms of cost-effectiveness: indirect chest X-ray vs LSCT. Nippon Igaku Hoshasen Gakkai Zasshi 54(10):943&#x02013;949<pub-id pub-id-type="pmid">7971185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>RM</given-names></name><name><surname>Atallah</surname><given-names>RP</given-names></name><name><surname>Struble</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Lung cancer screening with low-dose CT: a meta-analysis</article-title><source>J Gen Intern Med</source><year>2020</year><volume>35</volume><issue>10</issue><fpage>3015</fpage><lpage>3025</lpage><pub-id pub-id-type="doi">10.1007/s11606-020-05951-7</pub-id><pub-id pub-id-type="pmid">32583338</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hoffman RM, Atallah RP, Struble RD et al (2020) Lung cancer screening with low-dose CT: a meta-analysis. J Gen Intern Med 35(10):3015&#x02013;3025. 10.1007/s11606-020-05951-7<pub-id pub-id-type="pmid">32583338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Clavel</surname><given-names>C</given-names></name><name><surname>Petry</surname><given-names>KU</given-names></name><etal/></person-group><article-title>Overview of the European and North American studies on HPV testing in primary cervical cancer screening</article-title><source>Int J Cancer</source><year>2006</year><volume>119</volume><issue>5</issue><fpage>1095</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1002/ijc.21955</pub-id><pub-id pub-id-type="pmid">16586444</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Cuzick J, Clavel C, Petry KU et al (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119(5):1095&#x02013;1101. 10.1002/ijc.21955<pub-id pub-id-type="pmid">16586444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>RB</given-names></name><name><surname>Guido</surname><given-names>RS</given-names></name><name><surname>Castle</surname><given-names>PE</given-names></name><etal/></person-group><article-title>2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors</article-title><source>J Low Genit Tract Dis</source><year>2020</year><volume>24</volume><issue>2</issue><fpage>102</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1097/LGT.0000000000000525</pub-id><pub-id pub-id-type="pmid">32243307</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Perkins RB, Guido RS, Castle PE et al (2020) 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 24(2):102&#x02013;131<pub-id pub-id-type="pmid">32243307</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Uedo</surname><given-names>N</given-names></name><name><surname>Kamada</surname><given-names>T</given-names></name><etal/></person-group><article-title>Guidelines for endoscopic diagnosis of early gastric cancer</article-title><source>Dig Endosc</source><year>2020</year><volume>32</volume><issue>5</issue><fpage>663</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1111/den.13684</pub-id><pub-id pub-id-type="pmid">32275342</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yao K, Uedo N, Kamada T et al (2020) Guidelines for endoscopic diagnosis of early gastric cancer. Dig Endosc 32(5):663&#x02013;698. 10.1111/den.13684<pub-id pub-id-type="pmid">32275342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamashima</surname><given-names>C</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Shabana</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sensitivity of endoscopic screening for gastric cancer by the incidence method</article-title><source>Int J Cancer</source><year>2013</year><volume>133</volume><issue>3</issue><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1002/ijc.28065</pub-id><pub-id pub-id-type="pmid">23364866</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Hamashima C, Okamoto M, Shabana M et al (2013) Sensitivity of endoscopic screening for gastric cancer by the incidence method. Int J Cancer 133(3):653&#x02013;659. 10.1002/ijc.28065<pub-id pub-id-type="pmid">23364866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Toyoda</surname><given-names>Y</given-names></name><name><surname>Tabuchi</surname><given-names>T</given-names></name><name><surname>Hama</surname><given-names>H</given-names></name><etal/></person-group><article-title>Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: stomach, colorectum, lung, breast and cervix</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><issue>12</issue><fpage>e0244644</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0244644</pub-id><pub-id pub-id-type="pmid">33382821</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Toyoda Y, Tabuchi T, Hama H et al (2020) Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: stomach, colorectum, lung, breast and cervix. PLoS One 15(12):e0244644. 10.1371/journal.pone.0244644<pub-id pub-id-type="pmid">33382821</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Andrews</surname><given-names>KS</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening</article-title><source>CA Cancer J Clin</source><year>2019</year><volume>69</volume><issue>3</issue><fpage>184</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.3322/caac.21557</pub-id><pub-id pub-id-type="pmid">30875085</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Smith RA, Andrews KS, Brooks D et al (2019) Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 69(3):184&#x02013;210. 10.3322/caac.21557<pub-id pub-id-type="pmid">30875085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">GOV.UK (n.d.) Official website of the UK government. <ext-link ext-link-type="uri" xlink:href="https://www.gov.uk/">https://www.gov.uk/</ext-link>. Accessed 9 Jan 2025</mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Uematsu</surname><given-names>T</given-names></name></person-group><article-title>Rethinking screening mammography in Japan: next-generation breast cancer screening through breast awareness and supplemental ultrasonography</article-title><source>Breast Cancer</source><year>2024</year><volume>31</volume><issue>1</issue><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s12282-023-01506-w</pub-id><pub-id pub-id-type="pmid">37823977</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Uematsu T (2024) Rethinking screening mammography in Japan: next-generation breast cancer screening through breast awareness and supplemental ultrasonography. Breast Cancer 31(1):24&#x02013;30. 10.1007/s12282-023-01506-w<pub-id pub-id-type="pmid">37823977</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Uematsu</surname><given-names>T</given-names></name><name><surname>Izumori</surname><given-names>A</given-names></name><name><surname>Moon</surname><given-names>WK</given-names></name></person-group><article-title>Overcoming the limitations of screening mammography in Japan and Korea: a paradigm shift to personalized breast cancer screening based on ultrasonography</article-title><source>Ultrasonography</source><year>2023</year><volume>42</volume><issue>4</issue><fpage>508</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.14366/usg.23047</pub-id><pub-id pub-id-type="pmid">37697823</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Uematsu T, Izumori A, Moon WK (2023) Overcoming the limitations of screening mammography in Japan and Korea: a paradigm shift to personalized breast cancer screening based on ultrasonography. Ultrasonography 42(4):508&#x02013;517. 10.14366/usg.23047<pub-id pub-id-type="pmid">37697823</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">World Health Organization (2017) Guide to cancer early diagnosis. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789241511940">https://www.who.int/publications/i/item/9789241511940</ext-link>. Accessed 9 Jan 2025</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>von Euler-Chelpin</surname><given-names>M</given-names></name><name><surname>Lillholm</surname><given-names>M</given-names></name><name><surname>Vejborg</surname><given-names>I</given-names></name><etal/></person-group><article-title>Sensitivity of screening mammography by density and texture: a cohort study from a population-based screening program in Denmark</article-title><source>Breast Cancer Res</source><year>2019</year><volume>21</volume><issue>1</issue><fpage>111</fpage><pub-id pub-id-type="doi">10.1186/s13058-019-1203-3</pub-id><pub-id pub-id-type="pmid">31623646</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">von Euler-Chelpin M, Lillholm M, Vejborg I et al (2019) Sensitivity of screening mammography by density and texture: a cohort study from a population-based screening program in Denmark. Breast Cancer Res 21(1):111. 10.1186/s13058-019-1203-3<pub-id pub-id-type="pmid">31623646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Lukasiewicz</surname><given-names>S</given-names></name><name><surname>Czeczelewski</surname><given-names>M</given-names></name><name><surname>Forma</surname><given-names>A</given-names></name><etal/></person-group><article-title>Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review</article-title><source>Cancers (Basel)</source><year>2021</year><pub-id pub-id-type="doi">10.3390/cancers13174287</pub-id><pub-id pub-id-type="pmid">34830891</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lukasiewicz S, Czeczelewski M, Forma A et al (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 10.3390/cancers13174287<pub-id pub-id-type="pmid">34830891</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Kerlikowske</surname><given-names>K</given-names></name><name><surname>Grady</surname><given-names>D</given-names></name><name><surname>Barclay</surname><given-names>J</given-names></name><etal/></person-group><article-title>Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation</article-title><source>JAMA</source><year>1996</year><pub-id pub-id-type="doi">10.1001/jama.276.1.39</pub-id><pub-id pub-id-type="pmid">8667537</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kerlikowske K, Grady D, Barclay J et al (1996) Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA. 10.1001/jama.276.1.39<pub-id pub-id-type="pmid">8667537</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Raoof</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Jajoo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Multicancer early detection technologies: a review informed by past cancer screening studies</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2022</year><volume>31</volume><issue>6</issue><fpage>1139</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-21-1443</pub-id><pub-id pub-id-type="pmid">35320352</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Raoof S, Lee RJ, Jajoo K et al (2022) Multicancer early detection technologies: a review informed by past cancer screening studies. Cancer Epidemiol Biomarkers Prev 31(6):1139&#x02013;1145. 10.1158/1055-9965.EPI-21-1443<pub-id pub-id-type="pmid">35320352</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Lennon</surname><given-names>AM</given-names></name><name><surname>Buchanan</surname><given-names>AH</given-names></name><name><surname>Kinde</surname><given-names>I</given-names></name><etal/></person-group><article-title>Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention</article-title><source>Science</source><year>2020</year><pub-id pub-id-type="doi">10.1126/science.abb9601</pub-id><pub-id pub-id-type="pmid">32345712</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Lennon AM, Buchanan AH, Kinde I et al (2020) Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 10.1126/science.abb9601<pub-id pub-id-type="pmid">32345712</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname><given-names>A</given-names></name><name><surname>Cameron</surname><given-names>JM</given-names></name><name><surname>Brennan</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Global serum profiling: an opportunity for earlier cancer detection</article-title><source>J Exp Clin Cancer Res</source><year>2023</year><volume>42</volume><issue>1</issue><fpage>207</fpage><pub-id pub-id-type="doi">10.1186/s13046-023-02786-y</pub-id><pub-id pub-id-type="pmid">37580713</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Sala A, Cameron JM, Brennan PM et al (2023) Global serum profiling: an opportunity for earlier cancer detection. J Exp Clin Cancer Res 42(1):207. 10.1186/s13046-023-02786-y<pub-id pub-id-type="pmid">37580713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Brito-Rocha</surname><given-names>T</given-names></name><name><surname>Constancio</surname><given-names>V</given-names></name><name><surname>Henrique</surname><given-names>R</given-names></name><etal/></person-group><article-title>Shifting the cancer screening paradigm: the rising potential of blood-based multi-cancer early detection tests</article-title><source>Cells</source><year>2023</year><pub-id pub-id-type="doi">10.3390/cells12060935</pub-id><pub-id pub-id-type="pmid">36980276</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Brito-Rocha T, Constancio V, Henrique R et al (2023) Shifting the cancer screening paradigm: the rising potential of blood-based multi-cancer early detection tests. Cells. 10.3390/cells12060935<pub-id pub-id-type="pmid">36980276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>DC</given-names></name><name><surname>Gray</surname><given-names>DM</given-names><suffix>2nd</suffix></name><name><surname>Singh</surname><given-names>H</given-names></name><etal/></person-group><article-title>A cell-free DNA blood-based test for colorectal cancer screening</article-title><source>N Engl J Med</source><year>2024</year><volume>390</volume><issue>11</issue><fpage>973</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2304714</pub-id><pub-id pub-id-type="pmid">38477985</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Chung DC, Gray DM 2nd, Singh H et al (2024) A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med 390(11):973&#x02013;983. 10.1056/NEJMoa2304714<pub-id pub-id-type="pmid">38477985</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>EA</given-names></name><name><surname>Richards</surname><given-names>D</given-names></name><name><surname>Cohn</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><issue>9</issue><fpage>1167</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.05.806</pub-id><pub-id pub-id-type="pmid">34176681</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Klein EA, Richards D, Cohn A et al (2021) Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol 32(9):1167&#x02013;1177. 10.1016/j.annonc.2021.05.806<pub-id pub-id-type="pmid">34176681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Vittone</surname><given-names>J</given-names></name><name><surname>Gill</surname><given-names>D</given-names></name><name><surname>Goldsmith</surname><given-names>A</given-names></name><etal/></person-group><article-title>A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening</article-title><source>NPJ Precis Oncol</source><year>2024</year><volume>8</volume><issue>1</issue><fpage>91</fpage><pub-id pub-id-type="doi">10.1038/s41698-024-00568-z</pub-id><pub-id pub-id-type="pmid">38632333</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Vittone J, Gill D, Goldsmith A et al (2024) A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening. NPJ Precis Oncol 8(1):91. 10.1038/s41698-024-00568-z<pub-id pub-id-type="pmid">38632333</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>WS</given-names></name><name><surname>Patriotis</surname><given-names>C</given-names></name><name><surname>Dickherber</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cancer screening with multicancer detection tests: a translational science review</article-title><source>CA Cancer J Clin</source><year>2024</year><pub-id pub-id-type="doi">10.3322/caac.21833</pub-id><pub-id pub-id-type="pmid">38517462</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Rubinstein WS, Patriotis C, Dickherber A et al (2024) Cancer screening with multicancer detection tests: a translational science review. CA Cancer J Clin. 10.3322/caac.21833<pub-id pub-id-type="pmid">38517462</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Trosman</surname><given-names>JR</given-names></name><name><surname>Weldon</surname><given-names>CB</given-names></name><name><surname>Kurian</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy</article-title><source>Health Aff Sch</source><year>2023</year><pub-id pub-id-type="doi">10.1093/haschl/qxad005</pub-id><pub-id pub-id-type="pmid">38756840</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Trosman JR, Weldon CB, Kurian AW et al (2023) Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. Health Aff Sch. 10.1093/haschl/qxad005<pub-id pub-id-type="pmid">38756840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Tafazzoli</surname><given-names>A</given-names></name><name><surname>Ramsey</surname><given-names>SD</given-names></name><name><surname>Shaul</surname><given-names>A</given-names></name><etal/></person-group><article-title>EPR22&#x02013;119: cost-effectiveness of multi-cancer early detection (MCED) test in subgroups with smoking history or obesity</article-title><source>J Natl Comprehensive Cancer Network</source><year>2022</year><pub-id pub-id-type="doi">10.6004/jnccn.2021.7244</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Tafazzoli A, Ramsey SD, Shaul A et al (2022) EPR22&#x02013;119: cost-effectiveness of multi-cancer early detection (MCED) test in subgroups with smoking history or obesity. J Natl Comprehensive Cancer Network. 10.6004/jnccn.2021.7244</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Tafazzoli</surname><given-names>A</given-names></name><name><surname>Ramsey</surname><given-names>SD</given-names></name><name><surname>Shaul</surname><given-names>A</given-names></name><etal/></person-group><article-title>The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA</article-title><source>Pharmacoeconomics</source><year>2022</year><volume>40</volume><issue>11</issue><fpage>1107</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1007/s40273-022-01181-3</pub-id><pub-id pub-id-type="pmid">36038710</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tafazzoli A, Ramsey SD, Shaul A et al (2022) The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA. Pharmacoeconomics 40(11):1107&#x02013;1117. 10.1007/s40273-022-01181-3<pub-id pub-id-type="pmid">36038710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Kakushadze</surname><given-names>Z</given-names></name><name><surname>Raghubanshi</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name></person-group><article-title>Estimating Cost Savings from Early Cancer Diagnosis</article-title><source>Data</source><year>2017</year><volume>2</volume><issue>3</issue><fpage>30</fpage><pub-id pub-id-type="doi">10.3390/data2030030</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kakushadze Z, Raghubanshi R, Yu W (2017) Estimating Cost Savings from Early Cancer Diagnosis. Data 2(3):30</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Mariotto</surname><given-names>AB</given-names></name><name><surname>Enewold</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Medical care costs associated with cancer survivorship in the United States</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2020</year><volume>29</volume><issue>7</issue><fpage>1304</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-19-1534</pub-id><pub-id pub-id-type="pmid">32522832</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Mariotto AB, Enewold L, Zhao J et al (2020) Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev 29(7):1304&#x02013;1312. 10.1158/1055-9965.EPI-19-1534<pub-id pub-id-type="pmid">32522832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbell</surname><given-names>E</given-names></name><name><surname>Clarke</surname><given-names>CA</given-names></name><name><surname>Aravanis</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Modeled reductions in late-stage cancer with a multi-cancer early detection test</article-title><source>Cancer Epidemiol Biomark Prev</source><year>2021</year><volume>30</volume><issue>3</issue><fpage>460</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.Epi-20-1134</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Hubbell E, Clarke CA, Aravanis AM et al (2021) Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomark Prev 30(3):460&#x02013;468. 10.1158/1055-9965.Epi-20-1134</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>SJ</given-names></name><name><surname>Sly</surname><given-names>JR</given-names></name><name><surname>Rolfo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside</article-title><source>Health Affairs Scholar</source><year>2024</year><pub-id pub-id-type="doi">10.1093/haschl/qxae039</pub-id><pub-id pub-id-type="pmid">39677001</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Miller SJ, Sly JR, Rolfo C et al (2024) Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside. Health Affairs Scholar. 10.1093/haschl/qxae039<pub-id pub-id-type="pmid">39677001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Felekkis</surname><given-names>K</given-names></name><name><surname>Papaneophytou</surname><given-names>C</given-names></name></person-group><article-title>The circulating biomarkers league: combining miRNAs with cell-free DNAs and proteins</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>6</issue><fpage>3403</fpage><pub-id pub-id-type="doi">10.3390/ijms25063403</pub-id><pub-id pub-id-type="pmid">38542382</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Felekkis K, Papaneophytou C (2024) The circulating biomarkers league: combining miRNAs with cell-free DNAs and proteins. Int J Mol Sci 25(6):3403<pub-id pub-id-type="pmid">38542382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Oxnard</surname><given-names>G</given-names></name><name><surname>Klein</surname><given-names>E</given-names></name><name><surname>Seiden</surname><given-names>M</given-names></name><etal/></person-group><article-title>Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)</article-title><source>J Global Oncol</source><year>2019</year><volume>5</volume><fpage>44</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1200/JGO.2019.5.suppl.44</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Oxnard G, Klein E, Seiden M et al (2019) Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA). J Global Oncol 5:44&#x02013;44. 10.1200/JGO.2019.5.suppl.44</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>WS</given-names></name><name><surname>Patriotis</surname><given-names>C</given-names></name><name><surname>Dickherber</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cancer screening with multicancer detection tests: a translational science review</article-title><source>CA A Cancer J Clin</source><year>2024</year><pub-id pub-id-type="doi">10.3322/caac.21833</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Rubinstein WS, Patriotis C, Dickherber A et al (2024) Cancer screening with multicancer detection tests: a translational science review. CA A Cancer J Clin. 10.3322/caac.21833</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>C</given-names></name><name><surname>Jylha</surname><given-names>C</given-names></name><name><surname>de Stahl</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Simultaneous ultra-sensitive detection of structural and single nucleotide variants using multiplex droplet digital PCR in liquid biopsies from children with medulloblastoma</article-title><source>Cancers (Basel)</source><year>2023</year><pub-id pub-id-type="doi">10.3390/cancers15071972</pub-id><pub-id pub-id-type="pmid">38067365</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Arthur C, Jylha C, de Stahl TD et al (2023) Simultaneous ultra-sensitive detection of structural and single nucleotide variants using multiplex droplet digital PCR in liquid biopsies from children with medulloblastoma. Cancers (Basel). 10.3390/cancers15071972<pub-id pub-id-type="pmid">38067365</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Hackshaw</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>SS</given-names></name><name><surname>Reichert</surname><given-names>H</given-names></name><etal/></person-group><article-title>Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK</article-title><source>Br J Cancer</source><year>2021</year><volume>125</volume><issue>10</issue><fpage>1432</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01498-4</pub-id><pub-id pub-id-type="pmid">34426664</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Hackshaw A, Cohen SS, Reichert H et al (2021) Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Br J Cancer 125(10):1432&#x02013;1442. 10.1038/s41416-021-01498-4<pub-id pub-id-type="pmid">34426664</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>EA</given-names></name><name><surname>Madhavan</surname><given-names>S</given-names></name><name><surname>Beer</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Dying to find out: the cost of time at the dawn of the multicancer early detection era</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2023</year><volume>32</volume><issue>8</issue><fpage>1003</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-22-1275</pub-id><pub-id pub-id-type="pmid">37255363</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Klein EA, Madhavan S, Beer TM et al (2023) Dying to find out: the cost of time at the dawn of the multicancer early detection era. Cancer Epidemiol Biomarkers Prev 32(8):1003&#x02013;1010. 10.1158/1055-9965.EPI-22-1275<pub-id pub-id-type="pmid">37255363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Deverka</surname><given-names>PA</given-names></name><name><surname>Douglas</surname><given-names>MP</given-names></name><name><surname>Phillips</surname><given-names>KA</given-names></name></person-group><article-title>Multicancer screening tests: anticipating and addressing considerations for payer coverage and patient access</article-title><source>Health Aff (Millwood)</source><year>2022</year><volume>41</volume><issue>3</issue><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.2021.01316</pub-id><pub-id pub-id-type="pmid">35254936</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Deverka PA, Douglas MP, Phillips KA (2022) Multicancer screening tests: anticipating and addressing considerations for payer coverage and patient access. Health Aff (Millwood) 41(3):383&#x02013;389. 10.1377/hlthaff.2021.01316<pub-id pub-id-type="pmid">35254936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>SJ</given-names></name><name><surname>Sly</surname><given-names>JR</given-names></name><name><surname>Rolfo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside</article-title><source>Health Aff Sch</source><year>2024</year><pub-id pub-id-type="doi">10.1093/haschl/qxae039</pub-id><pub-id pub-id-type="pmid">39677001</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Miller SJ, Sly JR, Rolfo C et al (2024) Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside. Health Aff Sch. 10.1093/haschl/qxae039<pub-id pub-id-type="pmid">39677001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Minasian</surname><given-names>LM</given-names></name><name><surname>Pinsky</surname><given-names>P</given-names></name><name><surname>Katki</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Study design considerations for trials to evaluate multicancer early detection assays for clinical utility</article-title><source>J Natl Cancer Inst</source><year>2023</year><volume>115</volume><issue>3</issue><fpage>250</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1093/jnci/djac218</pub-id><pub-id pub-id-type="pmid">36458902</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Minasian LM, Pinsky P, Katki HA et al (2023) Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. J Natl Cancer Inst 115(3):250&#x02013;257. 10.1093/jnci/djac218<pub-id pub-id-type="pmid">36458902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Minasian</surname><given-names>LM</given-names></name><name><surname>Pinsky</surname><given-names>P</given-names></name><name><surname>Katki</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Study design considerations for trials to evaluate multicancer early detection assays for clinical utility</article-title><source>JNCI J Natl Cancer Institute</source><year>2022</year><pub-id pub-id-type="doi">10.1093/jnci/djac218</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Minasian LM, Pinsky P, Katki HA et al (2022) Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. JNCI J Natl Cancer Institute. 10.1093/jnci/djac218</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Johnson P (2024) An update on the ongoing NHS-Galleri trial. NHS England Blog. <ext-link ext-link-type="uri" xlink:href="https://www.england.nhs.uk/blog/an-update-on-the-ongoing-nhs-galleri-trial/">https://www.england.nhs.uk/blog/an-update-on-the-ongoing-nhs-galleri-trial/</ext-link>. Accessed 9 Jan 2025</mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Detection and localization of surgically resectable cancers with a multi-analyte blood test</article-title><source>Science</source><year>2018</year><volume>359</volume><issue>6378</issue><fpage>926</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1126/science.aar3247</pub-id><pub-id pub-id-type="pmid">29348365</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Cohen JD, Li L, Wang Y et al (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359(6378):926&#x02013;930. 10.1126/science.aar3247<pub-id pub-id-type="pmid">29348365</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Gainhullin V et al (2024) Abstract #LB100/11. AACR Annual Meeting 2024, San Diego, CA</mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Akolkar</surname><given-names>D</given-names></name><name><surname>Patil</surname><given-names>D</given-names></name><name><surname>Crook</surname><given-names>T</given-names></name><etal/></person-group><article-title>Circulating ensembles of tumor-associated cells: a redoubtable new systemic hallmark of cancer</article-title><source>Int J Cancer</source><year>2020</year><volume>146</volume><issue>12</issue><fpage>3485</fpage><lpage>3494</lpage><pub-id pub-id-type="doi">10.1002/ijc.32815</pub-id><pub-id pub-id-type="pmid">31785151</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Akolkar D, Patil D, Crook T et al (2020) Circulating ensembles of tumor-associated cells: a redoubtable new systemic hallmark of cancer. Int J Cancer 146(12):3485&#x02013;3494. 10.1002/ijc.32815<pub-id pub-id-type="pmid">31785151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Ranade</surname><given-names>A</given-names></name><name><surname>Bhatt</surname><given-names>A</given-names></name><name><surname>Page</surname><given-names>R</given-names></name><etal/></person-group><article-title>Hallmark circulating tumor-associated cell clusters signify 230 times higher one-year cancer risk</article-title><source>Cancer Prev Res (Phila)</source><year>2021</year><volume>14</volume><issue>1</issue><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-20-0322</pub-id><pub-id pub-id-type="pmid">32958586</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Ranade A, Bhatt A, Page R et al (2021) Hallmark circulating tumor-associated cell clusters signify 230 times higher one-year cancer risk. Cancer Prev Res (Phila) 14(1):11&#x02013;16. 10.1158/1940-6207.CAPR-20-0322<pub-id pub-id-type="pmid">32958586</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>T</given-names></name><name><surname>Leonard</surname><given-names>R</given-names></name><name><surname>Mokbel</surname><given-names>K</given-names></name><etal/></person-group><article-title>Accurate screening for early-stage breast cancer by detection and profiling of circulating tumor cells</article-title><source>Cancers (Basel)</source><year>2022</year><pub-id pub-id-type="doi">10.3390/cancers14143341</pub-id><pub-id pub-id-type="pmid">35884402</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Crook T, Leonard R, Mokbel K et al (2022) Accurate screening for early-stage breast cancer by detection and profiling of circulating tumor cells. Cancers (Basel). 10.3390/cancers14143341<pub-id pub-id-type="pmid">35884402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Bratulic</surname><given-names>S</given-names></name><name><surname>Limeta</surname><given-names>A</given-names></name><name><surname>Dabestani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Noninvasive detection of any-stage cancer using free glycosaminoglycans</article-title><source>Proc Natl Acad Sci U S A</source><year>2022</year><volume>119</volume><issue>50</issue><fpage>e2115328119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2115328119</pub-id><pub-id pub-id-type="pmid">36469776</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Bratulic S, Limeta A, Dabestani S et al (2022) Noninvasive detection of any-stage cancer using free glycosaminoglycans. Proc Natl Acad Sci U S A 119(50):e2115328119. 10.1073/pnas.2115328119<pub-id pub-id-type="pmid">36469776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>TF</given-names></name><name><surname>Shenoy</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Comparison of urine cell-free DNA with blood-based screening for detection of bladder cancer</article-title><source>J Clin Oncol</source><year>2023</year><pub-id pub-id-type="doi">10.1200/JCO.2023.41.6_suppl.457</pub-id><pub-id pub-id-type="pmid">36921335</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Stewart TF, Shenoy A, Stuart SM et al (2023) Comparison of urine cell-free DNA with blood-based screening for detection of bladder cancer. J Clin Oncol. 10.1200/JCO.2023.41.6_suppl.457<pub-id pub-id-type="pmid">36921335</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">NIH launches research network to evaluate emerging cancer screening technologies. <ext-link ext-link-type="uri" xlink:href="https://www.nih.gov/news-events/news-releases/nih-launches-research-network-evaluate-emerging-cancer-screening-technologies">https://www.nih.gov/news-events/news-releases/nih-launches-research-network-evaluate-emerging-cancer-screening-technologies</ext-link> (February 21, 2024). Accessed 25 June 2024</mixed-citation></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Smittenaar</surname><given-names>R</given-names></name><name><surname>Quaife</surname><given-names>SL</given-names></name><name><surname>von Wagner</surname><given-names>C</given-names></name><etal/></person-group><article-title>Impact of screening participation on modelled mortality benefits of a multi-cancer early detection test by socioeconomic group in England</article-title><source>J Epidemiol Commun Health</source><year>2024</year><volume>78</volume><issue>6</issue><fpage>345</fpage><pub-id pub-id-type="doi">10.1136/jech-2023-220834</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Smittenaar R, Quaife SL, von Wagner C et al (2024) Impact of screening participation on modelled mortality benefits of a multi-cancer early detection test by socioeconomic group in England. J Epidemiol Commun Health 78(6):345. 10.1136/jech-2023-220834</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Gelhorn</surname><given-names>H</given-names></name><name><surname>Ross</surname><given-names>MM</given-names></name><name><surname>Kansal</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Patient preferences for multi-cancer early detection (MCED) screening tests</article-title><source>Patient</source><year>2023</year><volume>16</volume><issue>1</issue><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1007/s40271-022-00589-5</pub-id><pub-id pub-id-type="pmid">35844011</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Gelhorn H, Ross MM, Kansal AR et al (2023) Patient preferences for multi-cancer early detection (MCED) screening tests. Patient 16(1):43&#x02013;56. 10.1007/s40271-022-00589-5<pub-id pub-id-type="pmid">35844011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Trosman</surname><given-names>JR</given-names></name><name><surname>Weldon</surname><given-names>CB</given-names></name><name><surname>Kurian</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy</article-title><source>Health Affairs Scholar</source><year>2023</year><pub-id pub-id-type="doi">10.1093/haschl/qxad005</pub-id><pub-id pub-id-type="pmid">38756840</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Trosman JR, Weldon CB, Kurian AW et al (2023) Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. Health Affairs Scholar. 10.1093/haschl/qxad005<pub-id pub-id-type="pmid">38756840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Schrag</surname><given-names>D</given-names></name><name><surname>Beer</surname><given-names>TM</given-names></name><name><surname>McDonnell</surname><given-names>CH</given-names><suffix>3rd</suffix></name><etal/></person-group><article-title>Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study</article-title><source>Lancet</source><year>2023</year><volume>402</volume><issue>10409</issue><fpage>1251</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01700-2</pub-id><pub-id pub-id-type="pmid">37805216</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Schrag D, Beer TM, McDonnell CH 3rd et al (2023) Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 402(10409):1251&#x02013;1260. 10.1016/S0140-6736(23)01700-2<pub-id pub-id-type="pmid">37805216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>RD</given-names></name><name><surname>Johnson</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic prospective randomised controlled trial</article-title><source>Cancers (Basel).</source><year>2022</year><pub-id pub-id-type="doi">10.3390/cancers14194818</pub-id><pub-id pub-id-type="pmid">36497238</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Neal RD, Johnson P, Clarke CA et al (2022) Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic prospective randomised controlled trial. Cancers (Basel). 10.3390/cancers14194818<pub-id pub-id-type="pmid">36497238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>P</given-names></name><name><surname>Oldfield</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Early cancer detection in li-fraumeni syndrome with cell-free DNA</article-title><source>Cancer Discov</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>104</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-23-0456</pub-id><pub-id pub-id-type="pmid">37874259</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Wong D, Luo P, Oldfield LE et al (2024) Early cancer detection in li-fraumeni syndrome with cell-free DNA. Cancer Discov 14(1):104&#x02013;119. 10.1158/2159-8290.CD-23-0456<pub-id pub-id-type="pmid">37874259</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>